NewLink Genetics

NewLink Genetics’ official Twitter handle. We are at the forefront in immuno-oncology treatments and our passion is relentless.

[NewLink Genetics @NLNKGenetics]

Positive results presented today at #AACR19 from our Phase 2 study of NLG2017 to treat patients with refractory #ovariancancer @AACR

Click here for the official press release: https://t.co/osMBIE4gsM

[NewLink Genetics @NLNKGenetics]

We’re pleased to announce that results from our Phase 2 study of NLG207 has been accepted for presentation at the 2019 @AACR Annual Meeting in Atlanta, Georgia, Mar. 29 – Apr. 3. Learn more: https://t.co/UCxgEyQtEO
#AACR19 #ovariancancer $NLNK

[NewLink Genetics @NLNKGenetics]

Today, $NLNK reported Q4 and year-end 2018 financial results, progress in clinical development as well as programs and key 2019 priorities related to our clinical pipeline. Read more: https://t.co/D4GuUwOi17

[NewLink Genetics @NLNKGenetics]

Attending #IO360NYC? Don’t miss $NLNK CEO Charles Link Jr., MD, and his presentation, “IDO Changes the T-cell Balance in the Tumor Microenvironment.” To learn more, visit: https://t.co/vfSAkm36q4 #ImmunoOncology #oncology #indoximod @IO360summit

[NewLink Genetics @NLNKGenetics]

Today, our team at $NLNK is taking time to reflect on the global burden of #cancer and on our mission as a company. We will continue searching for answers and engaging with the #oncology community to advance cancer care for patients. #WorldCancerDay #IAmAndIWill @uicc

[NewLink Genetics @NLNKGenetics]

Monday, February 4th is #WorldCancerDay, focused on raising awareness about #cancer around the world to ensure that it remains a global health priority. $NLNK proudly supports this cause, organized by @uicc. This year’s theme is #IAmAndIWill @WorldCancerDay @AmericanCancer

[NewLink Genetics @NLNKGenetics]

Join $NLNK CEO, Charles Link Jr., MD, at the upcoming IO360° Conference, February 6-8 at the Crowne Plaza Hotel in Times Square.
Learn more: https://t.co/vfSAkm36q4
#io360nyc #ImmunoOncology #oncology #indoximod @IO360summit

[NewLink Genetics @NLNKGenetics]

Dr. Ashkan Emadi spoke to @ecancer TV at #ASH18 to explain updated results from a recent $NLNK #clinicaltrial for IDO pathway inhibitor, indoximod, in combination with chemotherapy for patients with #AML https://t.co/yOgNBQEqHu

[NewLink Genetics @NLNKGenetics]

NewLink presented updated Phase 1 #data at #ASH18 evaluating indoximod + chemotherapy for the treatment of #AML. View the official press release for more information: https://t.co/qR1t9lomGa

[NewLink Genetics @NLNKGenetics]

#ICYMI $NLNK will be giving an oral presentation, by Ashkan Emadi, MD, PhD, at #ASH18 on Sunday, Dec. 2, from 9:30-11:00 AM PT. Learn more: https://t.co/V9Z79oVXsW

[NewLink Genetics @NLNKGenetics]

We're heading to #ASH18 this week. Attending the conference? Stop by our oral presentation of #data pertaining to the use of our investigational immuno-oncology molecule, #indoximod, in combination therapy for patients with newly diagnosed #AML: https://t.co/V9Z79oVXsW

[NewLink Genetics @NLNKGenetics]

Congratulations to our partner @Merck, who announced the start of its rolling BLA submission to the @US_FDA for V920, a vaccine for #Ebola. Learn more: https://t.co/MPq042rSgN
$MRK $NLNK

[NewLink Genetics @NLNKGenetics]

There’s still time to stop by poster P706 from 7-8:30PM during #SITC2018 today to Gabriela Rossi, PhD & Jiayi Yu, PhD of $NLNK & learn about our biopsy data from a Ph2 study of #indoximod plus chemotherapy for patients with metastatic pancreatic #cancer: https://t.co/WWzSnNdpAA

[NewLink Genetics @NLNKGenetics]

#ICYMI Gabriela Rossi, PhD and Jiayi Yu, PhD of $NLNK are presenting a poster session today at 12:20-1:50PM and 7-8:30PM during #SITC2018 on our biopsy #data from a Ph2 study of #indoximod plus checkpoint inhibition from patients with advanced #melanoma: https://t.co/7yc3djPYrG

[NewLink Genetics @NLNKGenetics]

#ICYMI $NLNK will be presenting biopsy #data from a Phase 2 study of #indoximod plus chemotherapy for patients with metastatic pancreatic #cancer in poster session P706 at #SITC2018 today, Nov. 10, 12:20-1:50PM & 7:00-8:30PM to discuss this data: https://t.co/EzCFoUYSYz

[NewLink Genetics @NLNKGenetics]

At #SITC2018? Stop by poster P142 today at 12:20-1:50PM & 7-8:30PM to learn about our biopsy #data from a Ph2 study of #indoximod plus checkpoint inhibition from patients with advanced #melanoma presented by Gabriela Rossi, PhD and Jiayi Yu, PhD of $NLNK: https://t.co/s4LKTv0Q8h

[NewLink Genetics @NLNKGenetics]

Don’t forget to stop by poster session P331 today at 12:45-2:15PM and 6:30-8PM during #SITC2018 to see our preliminary #data from a Phase 1a study of NLG802, a prodrug of #indoximod, presented by $NLNK Chief Medical Officer Eugene Kennedy, MD. Learn more: https://t.co/DfKagN0Qmy

[NewLink Genetics @NLNKGenetics]

#ICYMI Eugene Kennedy, MD, of $NLNK will be presenting preliminary #data from a Phase 1a study of NLG802 in poster session P331 at #SITC2018 today, Nov. 9, 12:45-2:15PM and 6:30-8:00PM. Learn more: https://t.co/Niq44sDCcg

[NewLink Genetics @NLNKGenetics]

Today, we’re excited to announce the #data of 3 separate trials being presented in poster sessions at #SITC2018 on Nov. 9-10 – including #pharmacokinetic data from a Ph1a study of #NLG802 and #biomarker data from two Ph2 studies of #indoximod: https://t.co/T6Fvska4i0
$NLNK

[NewLink Genetics @NLNKGenetics]

$NLNK reported consolidated financial results for the third quarter 2018, announced abstracts to be presented at upcoming #medical meetings and reviewed recent highlights and upcoming milestones. Read more: https://t.co/OAFZxbYkj7